STOCK TITAN
  1. Home
  2. News
  3. IMCC

IM Cannabis Corp - IMCC STOCK NEWS

Welcome to our dedicated news page for IM Cannabis (Ticker: IMCC), a resource for investors and traders seeking the latest updates and insights on IM Cannabis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IM Cannabis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IM Cannabis's position in the market.

News
IMC Announces the Conclusion of the Planning and Construction Legal Proceedings
Rhea-AI Summary
IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) announces the conclusion of construction proceedings against Focus Medical Herbs Ltd. with a fine of CAD$129,000 imposed. The company maintains control of Focus Medical and continues its operations in Israel and Germany.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
none
-
News
New Israeli cannabis regulation, facilitating access for many new patients, scheduled for December 29, 2023, has been postponed by three months; Israeli Ministry of Health published a new report showing a surge in new medical cannabis patients in November 2023
Rhea-AI Summary
IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) announces a 3-month delay in the implementation of the anticipated medical cannabis reform in Israel due to the Israel-Hamas war. The delay is expected to postpone the regulatory reform, designed to enhance access to medical cannabis for patients, originally scheduled for December 29, 2023. The Ministry of Health also reported a significant surge in the number of new medical cannabis patients in November 2023, with 3,254 new patients receiving licenses, the largest increase since 2021.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
none
-
News
IM Cannabis Announces Receipt of Court Action
Rhea-AI Summary
IM Cannabis Corp. (IMCC) Faces $15 Million Lawsuit Over Alleged Misrepresentations in Disclosures Prior to IMC/MYM Transaction
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
News
IM Cannabis Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) announced its Q3 2023 financial results, reporting a 6.6% decrease in revenue, a 10% increase in gross margin, and a 30% increase in gross profit. The company focused on active cost management and margin improvement while facing currency fluctuations and the impact of the conflict between Hamas and Israel on the medical cannabis industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
earnings
-
News
IM Cannabis to Report Third Quarter 2023 Financial Results on Monday, November 13 at 9:00am ET
Rhea-AI Summary
IM Cannabis Corp (IMCC) to release Q2 2023 operational and financial results on November 13, 2023, followed by a zoom web conference at 9:00 a.m. ET. Investors can register for the conference and access the call recording on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
conferences earnings
-
News
IM Cannabis Releases a Message from the CEO about the Israel-Hamas War and announces securing C$1,390,000 in Short-Term Debt
Rhea-AI Summary
IM Cannabis Corp. secures C$1,390,000 in short-term debt amid Israel-Hamas War
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.97%
Tags
none
News
IM Cannabis Announces the appointment of Uri Birenberg as Chief Financial Officer
Rhea-AI Summary
IM Cannabis Corp. announces Uri Birenberg as new Chief Financial Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
management
-
News
IM Cannabis Announces CFO Departure
Rhea-AI Summary
IM Cannabis Corp's Chief Financial Officer, Itay Vago, will be leaving the company for personal reasons. He will continue to serve as CFO until the publication of Q3 2023 results. The company has started searching for a new CFO. No concrete positive or negative impacts on stock price are indicated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
none
-
News
IM Cannabis Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
IM Cannabis Corp. (NASDAQ: IMCC) reported its Q2 2023 financial results, with revenues increasing by 4% YoY to $13.2 million. Gross margin increased by 40%, and Non-IFRS Adjusted EBITDA Loss decreased by 83%. Operating expenses decreased by 33%. The company focused on active cost management and margin improvement while maintaining sales. IMC Israel launched new high THC strains and entered the midrange market. IMC Germany onboarded four new customers and utilized its fully licensed EU-GMP packing facility and GDP logistics center.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.73%
Tags
earnings
News
IMC welcomes new Israeli cannabis regulations which are about to change significantly, facilitating access for many new patients
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
none
Stock IMCC logo
IM Cannabis Corp

Nasdaq:IMCC

IMCC Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

IMCC Stock Data

8.68M
8.59M
36.09%
8.15%
0.73%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Israel
Tel Aviv

About IMCC

premium medical cannabis products for global consumers – im cannabis (imc) is one of the world's pioneering medical-grade cannabis companies, with operations in israel, across europe, and canada. over the past decade, imc has established its premium medical cannabis brand, comprising a full spectrum of products known for their quality, consistency, and purity, such as 'roma', 'tel aviv' and 'london'. in europe, imc has established a fully operational, vertically integrated medical cannabis business, spearheaded by its eu-gmp certified distribution arm in germany and augmented by strategic alliances with certified pan-eugmp certified suppliers. to this end, imc has formed strong strategic alliances within the international medical cannabis industry, aiming for a dominant position in satisfying the global demand for high-quality medical cannabis products, which both physicians and patients can rely upon. imc further intends to leverage its expertise in israel in order to bolster its res